证券记录 · 已归档季度
BMRN
BioMarin Pharmaceutical Inc. · Healthcare · Biotechnology
22被追踪持有人
-2Δ持有人
113.78M持有股份
$6.25B报告持仓市值
+0新建仓位
−2清仓
动量输入（同类管理人）：
持有人广度 -8.3% ·
股份流向 -0.3% ·
净新建仓位 -9.1%
· 公式
广泛减持：持股数量下降，持有人数量减少
所有持股数据：仅限已追踪的 13F 管理人，普通股持仓，报告期 Q2 2025
持股变化趋势
| 季度 | 持有人 | Δ | 股份 | 报告持仓市值 | 新增 | 清仓 |
|---|---|---|---|---|---|---|
| Q3 2026 | 2 | 0 | 1.42M | $84.45M | n/a | −2 |
| Q2 2026 | 135 | +4 | 146.70M | $8.39B | +11 | −8 |
| Q1 2026 | 135 | -4 | 142.18M | $8.03B | +5 | −10 |
| Q4 2025 | 138 | +3 | 154.93M | $9.20B | +4 | n/a |
| Q3 2025 | 23 | -1 | 108.93M | $5.90B | n/a | −2 |
| Q2 2025 | 22 | -2 | 113.78M | $6.25B | n/a | −2 |
| Q1 2025 | 21 | 0 | 70.58M | $4.99B | +1 | −1 |
| Q4 2024 | 21 | +1 | 67.83M | $4.46B | +1 | n/a |
| Q3 2024 | 19 | 0 | 57.19M | $4.02B | +2 | −2 |
| Q2 2024 | 19 | n/a | 53.80M | $4.43B | n/a | n/a |
持有人 · Q2 2025
| # | 管理人 | 股份 | Δ股份 | 价值 | 其权重 | 持有 | ||
|---|---|---|---|---|---|---|---|---|
| 1 | BlackRock ✦ (被动) | 24.00M | n/a | $1.32B | 0.0% | n/c | 1 | SEC ↗ ×22 |
| 2 | The Vanguard Group ✦ (被动) | 19.00M | n/a | $1.04B | 0.0% | n/c | 1 | SEC ↗ ×6 |
| 3 | PRIMECAP Management ✦ | 15.77M | -11.3% | $867.00M | 0.7% | ▼ Trim | 5 | SEC ↗ |
| 4 | Dodge & Cox ✦ | 15.11M | +1.0% | $830.50M | 0.5% | ▲ Add | 5 | SEC ↗ |
| 5 | Viking Global Investors ✦ | 12.29M | +13.8% | $675.50M | 2.0% | ▲ Add | 5 | SEC ↗ |
| 6 | State Street Global Advisors ✦ (被动) | 8.85M | +4.5% | $486.36M | 0.0% | ▲ Add | 3 | SEC ↗ |
| 7 | AQR Capital Management ✦ | 5.58M | +90.7% | $306.43M | 0.3% | ▲ Add | 5 | SEC ↗ ×7 |
| 8 | Geode Capital Management ✦ (被动) | 3.47M | +1.3% | $190.42M | 0.0% | ▲ Add | 5 | SEC ↗ ×2 |
| 9 | Millennium Management ✦ | 2.83M | +319.7% | $155.80M | 0.1% | ▲ Add | 5 | SEC ↗ |
| 10 | Norges Bank ✦ (被动) | 2.04M | -38.2% | $112.35M | 0.0% | ▼ Trim | 5 | SEC ↗ |
| 11 | Renaissance Technologies ✦ | 1.81M | +101.7% | $99.32M | 0.1% | ▲ Add | 5 | SEC ↗ |
| 12 | D. E. Shaw & Co. ✦ | 1.12M | +104.4% | $61.32M | 0.1% | ▲ Add | 5 | SEC ↗ ×2 |
| 13 | Fidelity (FMR) ✦ | 546.10K | n/a | $30.02M | 0.0% | n/c | 1 | SEC ↗ ×4 |
| 14 | Citadel Advisors ✦ | 335.02K | -79.0% | $18.42M | 0.0% | ▼ Trim | 5 | SEC ↗ ×2 |
| 15 | Arrowstreet Capital ✦ | 278.64K | +27.8% | $15.32M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 16 | Bridgewater Associates ✦ | 227.75K | +84.2% | $12.52M | 0.1% | ▲ Add | 5 | SEC ↗ |
| 17 | Two Sigma Investments ✦ | 147.60K | -80.6% | $8.11M | 0.0% | ▼ Trim | 5 | SEC ↗ |
| 18 | T. Rowe Price ✦ | 137.93K | +4.2% | $7.58M | 0.0% | ▲ Add | 5 | SEC ↗ ×2 |
| 19 | Gotham Asset Management ✦ | 119.45K | +151.6% | $6.57M | 0.0% | ▲ Add | 4 | SEC ↗ |
| 20 | Marshall Wace ✦ | 83.85K | +484.9% | $4.61M | 0.0% | ▲ Add | 3 | SEC ↗ ×3 |
| 21 | Fisher Asset Management ✦ | 13.54K | -0.2% | $744,581 | 0.0% | ▼ Trim | 5 | SEC ↗ |
| 22 | GAMCO Investors ✦ | 8.00K | -3.5% | $439,760 | 0.0% | ▼ Trim | 5 | SEC ↗ |
"持仓权重"指该仓位占该管理人13F申报股票组合市值的比例，即持仓信心指标。✦ = 精选管理人。
新增买入方
| 本季度无新增被追踪买入方。 |
已清仓
| Elliott Investment Management | $247.44M | 曾为 2.3% |
| Point72 Asset Management | $27.98M | 曾为 0.1% |
全市场背景: 涵盖所有13F申报机构（SEC结构化数据， Q1 2026): 549 持有人, 183.01M 股份, $10.09B 已申报. 这是与上方被追踪全域数据不同的较早期间，两者从不混用。
常见共同持仓
持有该证券的受追踪机构最常同时持有的其他证券：基于共同持有计数，而非基本面关联。
公开市场买入 (P)
在我们的覆盖窗口内无内部人士公开市场买入记录。
公开市场卖出 (S)
Sep 02
Davis George Eric
Officer · 17.56K 股 · $1.16M
授予、行权及税务代扣代缴在本平台均不计入买入或卖出。 方法论
数据来源: 持股数据来源于已解析的13F普通股持仓（被追踪范围，变动对比集）；内部人行为来自Form 3/4/5；重大持股来自Schedule 13D/13G；所有文件均链接至SEC EDGAR原始申报。
报告期: Q2 2025 ·
方法论 ·
通过API获取此数据